10-Q: Ainos Secures $2.1M AI Nose Order, Regains Nasdaq Compliance

Ainos, Inc. reported increased net losses for Q2 and H1 2025, but secured a significant $2.1 million AI Nose order with ASE and regained Nasdaq minimum bid price compliance.

Summary

• Net loss for Q2 2025 increased by 28% to $4,084,990 compared to $3,195,022 in Q2 2024.
• Net loss for H1 2025 increased by 13% to $7,371,012 compared to $6,509,832 in H1 2024.
• Revenue for Q2 2025 was $4,663, up from $0 in Q2 2024, primarily from VELDONA pet supplements.
• Revenue for H1 2025 increased by 435% to $110,870, driven by VOC sensing products related to NISD co-development.
• Gross profit for Q2 2025 was $3,726, a significant improvement from a $25,373 gross loss in Q2 2024.
• Gross profit for H1 2025 was $91,700, reversing a $31,398 gross loss in H1 2024.
• Operating loss increased by 23% in Q2 2025 to $3,745,687 and by 12% in H1 2025 to $6,908,558.
• Cash and cash equivalents decreased to $1,223,184 as of June 30, 2025, from $3,892,919 at December 31, 2024.
• The company completed a 1-for-5 reverse stock split on June 30, 2025, to maintain Nasdaq listing compliance.
• Ainos regained compliance with Nasdaq's minimum $1.00 bid price requirement on July 15, 2025.
• Secured a three-year, $2.1 million subscription-based order with ASE Technology Holding Co., Ltd. for 1,400 AI Nose units, launching a 'SmellTech-as-a-Service' model.
• Sold an aggregate of 262,383 shares under an At The Market (ATM) offering for net proceeds of $719,358 as of June 30, 2025, with an additional $1,049,898 raised from July 1 to August 13, 2025.
• Repaid the $1,000,000 principal plus accrued interest of $132,650 for the Lee Note on April 30, 2025.
• The ASE Note maturity date was extended to March 12, 2027, with an adjusted conversion price.

Sentiment

Score: 3

Explanation: While the company secured a notable order and regained Nasdaq compliance, these positives are overshadowed by significantly increased net losses, a rapidly dwindling cash balance, and explicit 'going concern' doubts. The repeated reverse stock splits indicate fundamental issues with valuation and investor confidence. The company is burning cash and relies heavily on future financing, which is uncertain.

Positives

• Secured a significant three-year, $2.1 million subscription-based order with ASE Technology Holding Co., Ltd. for 1,400 AI Nose units, validating the 'SmellTech-as-a-Service' model.
• Regained compliance with Nasdaq's minimum $1.00 bid price requirement on July 15, 2025, resolving a previous deficiency notice.
• Revenue for H1 2025 increased by 435% to $110,870, primarily due to VOC sensing products related to NISD co-development.
• Gross profit improved significantly, moving from a loss of $31,398 in H1 2024 to a profit of $91,700 in H1 2025.
• Net cash used in operating activities decreased to $2,575,000 in H1 2025 from $3,468,892 in H1 2024, indicating improved operational cash efficiency.
• Net cash used in investing activities decreased significantly to $18,045 in H1 2025 from $119,792 in H1 2024.
• The VELDONA platform's HIV oral wart program has received Orphan Drug Designation from the U.S. FDA.

Negatives

• Net loss increased by 28% in Q2 2025 to $4,084,990 and by 13% in H1 2025 to $7,371,012, indicating continued unprofitability.
• Cash and cash equivalents decreased substantially to $1,223,184 as of June 30, 2025, from $3,892,919 at December 31, 2024.
• Accumulated deficit increased to $60,120,328 as of June 30, 2025, from $52,749,316 at December 31, 2024.
• Operating loss increased by 23% in Q2 2025 and 12% in H1 2025, reflecting expanding operating expenses.
• Selling, General and Administrative (SG&A) expenses increased by 76% in Q2 2025 and 62% in H1 2025, largely due to share-based compensation.
• Interest expense increased by 50% in Q2 2025 and 114% in H1 2025 due to higher principal amounts of convertible notes.
• The company effected a third reverse stock split (1-for-5) on June 30, 2025, following previous splits in 2022 and 2023, indicating persistent issues with maintaining share price.
• Substantial doubt exists about the company's ability to continue as a going concern for at least one year from the issuance of these financial statements.

Risks

• Fluctuating foreign currency and exchange rates may negatively impact business, results of operations, and financial position, especially given foreign operations and cash holdings in Taiwan.
• Policy changes affecting international trade, such as tariffs, import/export licensing, economic sanctions, or new barriers to entry, could adversely impact product demand and competitive position.
• The company has incurred net operating losses since inception and has an accumulated deficit of $60,120,328, with expectations of continued losses and negative operating cash flows for at least the next twelve months.
• Substantial doubt exists about the company's ability to continue as a going concern for at least one year, dependent on generating sufficient cash flows or obtaining additional financing.
• The industry is characterized by extensive patent litigation, and competitors may claim infringement, leading to costly and time-consuming legal proceedings, significant damage awards, or injunctions.

Future Outlook

The company's top near-term priority is scaling the AI Nose platform in industrial, robotics, and long-term care settings through partnerships and a subscription-based 'SmellTech-as-a-Service' model, aiming for recurring revenue. It plans to continue targeted, capital-efficient clinical validation of Ainos Flora in Taiwan and explore potential partnerships or licensing opportunities. VELDONA programs will advance through cost-effective clinical studies in Taiwan, balancing development progress with capital discipline. The company anticipates business revenues and external financing options to fund operations over the next twelve months, but acknowledges that capital resources could be exhausted sooner than expected and additional capital raises may be necessary.

Management Comments

• We continued to invest resources to execute our growth strategy and product roadmap to improve our profitability.
• We expect that our R&D expenses related to clinical trials will continue to grow as we further develop AI Nose, VOC POCT and VELDONA drug candidates.
• We anticipate business revenues and external financing options, if necessary, to fund our operations over the next twelve months.
• There can be no assurance that we will be successful in our efforts to make the Company profitable. If those efforts are not successful, the Company may raise additional capital through the issuance of equity securities, debt financings or other sources to further implement its business plan.

Industry Context

Ainos operates in the rapidly evolving fields of artificial intelligence (AI) for scent digitization and healthcare, including point-of-care testing and therapeutics. The company's focus on AI Nose for industrial and robotics applications aligns with broader industry trends towards automation, smart manufacturing, and predictive maintenance. Its 'SmellTech-as-a-Service' model is a strategic move to generate recurring revenue, mirroring the prevalent SaaS trend in technology. In healthcare, the development of VELDONA for rare, autoimmune, and infectious diseases, particularly with Orphan Drug Designation, positions it in a high-value, specialized market. The partnerships with major players like ASE Technology Holding Co., Ltd. and ugo, Inc. suggest a strategy to integrate its niche AI technology into established industrial and robotics ecosystems, potentially accelerating market penetration and adoption.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks.

Corporate Governance

Legal Proceedings

• The company operates in an industry characterized by extensive patent litigation, where competitors may claim infringement. Resolution of such claims is typically time-consuming and costly, potentially resulting in significant damage awards or injunctions.
• As of June 30, 2025, the company was not aware of any material legal proceedings involving it.

Related Party Transactions

• Working capital advances: Total interest expense incurred in related to the KY Note and ASE Note for the six months ended June 30, 2025, was $336,569 (compared to $132,855 for the same period in 2024). Unpaid accrued interest expenses were $876,608 as of June 30, 2025.
• Product Co-development Agreement with Taiwan Carbon Nano Technology Corporation (TCNT): Development expenses were $173,672 for the six months ended June 30, 2025 (compared to $191,838 for the same period in 2024).
• Fee for non-exclusive use of patents with TCNT: $308,013 for the six months ended June 30, 2025 (compared to $569,862 for the same period in 2024).
• Convertible Note Issued to ASE Test, Inc. (a shareholder of Ainos KY): ASE committed to pay $2,000,000 in exchange for convertible promissory notes. The maturity date was extended to March 12, 2027, and the conversion price was adjusted.
• May 2027 Convertible Notes and Warrant Purchase Agreement with ASE Test, Inc.: Issued convertible promissory notes with 6% compound interest in the aggregate principal amount of $9,000,000 and warrants for up to 500,000 shares.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing capital raises (ATM offering) and past/future reverse stock splits. The 'going concern' doubt poses a substantial risk to investment value. The new ASE order and Nasdaq compliance offer some positive sentiment but are offset by continued losses.
• **Employees**: Share-based compensation is a significant component of SG&A, indicating reliance on equity incentives. Continued losses and 'going concern' issues could impact job security and future equity value.
• **Creditors (Convertible Note Holders)**: The company has extended maturity dates for some convertible notes and repaid others, indicating active management of debt. However, the 'going concern' risk could affect repayment ability.
• **Customers (ASE Technology Holding Co., Ltd.)**: The $2.1 million order for AI Nose units signifies a strong partnership and potential for long-term engagement, benefiting both parties through enhanced manufacturing and recurring revenue for Ainos.
• **Partners (ugo, Kenmec, Solomon, NISD)**: Ongoing co-development and marketing agreements indicate active collaboration, which could lead to broader market adoption of Ainos' technologies and shared success, but also expose partners to Ainos' financial risks.

Next Steps

• Scale the AI Nose platform in industrial, robotics, and long-term care settings through partnerships and a subscription-based model over the second half of 2025.
• Enter Taiwan clinical trials for VELDONA's two lead indications: HIV-related oral warts and Sjogren's syndrome.
• Continue targeted, capital-efficient clinical validation of Ainos Flora in Taiwan.
• Explore potential partnerships or licensing opportunities for AI Nose, POCT, and VELDONA programs.
• Increase clinical trial spending to advance VOC POCT and VELDONA drug candidates.
• Potentially increase sales and marketing efforts.
• Seek additional equity and/or debt financing if current funding and revenues are insufficient to cover operations for the next twelve months.

Key Dates

Recommendation

Despite regaining Nasdaq compliance and securing a new order, Ainos, Inc. faces severe financial challenges, including significantly increased net losses, a rapidly depleting cash balance, and an explicit 'going concern' warning. The company's reliance on repeated reverse stock splits to maintain listing and continuous capital raises through ATM offerings indicate a precarious financial position and significant dilution risk for existing shareholders. While the AI Nose technology shows promise, the current financial instability and lack of clear path to profitability make the stock a high-risk investment with substantial downside potential. A seasoned investor would likely view the 'going concern' warning as a critical red flag, outweighing any operational positives.

Keywords

AI Nose, digital olfaction, VELDONA, low-dose oral interferon, point-of-care testing, POCT, SmellTech-as-a-Service, smart manufacturing, healthcare AI, biotechnology, pharmaceuticals, medical devices, reverse stock split, Nasdaq compliance, convertible notes, ASE Technology Holding, Taiwan Carbon Nano Technology, Sjogren's syndrome, HIV oral warts, feline chronic gingivostomatitis